About US
Contact us
-
Novartis: Alternative payments will ‘reset the paradigm’ for covering gene, cell therapiesWhen Dave Lennon, president of Novartis unitAveXis, said in November that the company’s experimental gene therapy to treat spinal muscular atrophy (SMA) could be cost-effective at a price of $4 millio2019/1/29
-
FDA finds more issues at Lupin plant it spanked in warning letterThe FDA in 2017 ripped Indian drugmaker Lupin in a warning letter for not learning from past mistakes. In a new visit to one of the two plants cited in that letter, the FDA has again found issues. Lu2019/1/28
-
Takeda’s dengue shot, rival to Sanofi's Dengvaxia, hits the mark in massive phase 3 studyIt’s no secret Sanofi has had trouble with its world-first dengue vaccine,Dengvaxia, but that hasn't dissuaded Takeda. Its own dengue shot met its goal in a pivotal phase 3 study that covered eight co2019/1/28
-
Bayer gets with the program for Super Bowl LIII to kick off cancer testing awareness effortBayer is going to the Super Bowl. Not with some glitzy $5 million TV ad, but instead with a print ad in the official Super Bowl LIII program to launch its new awareness campaign around genomic testing2019/1/25
-
Bristol-Myers, Roche will top burgeoning I-O market worth $29B: analystBristol-Myers Squibb may be falling behind in the metastatic cancer race, and Roche is dealing with biosimilarattacks on its top-selling drugs. But the two companies are the front-runners in the argua2019/1/25
-
Washington takes 'Netflix' hep C drug pricing further with winner-take-all biddingIt’s not just Louisianaworking to tackle hepatitis C by purchasing drugs in a novel way.Officials in Washington are taking that state's Netflix-style subscription model and upping the ante with a winn2019/1/24
-
Johnson & Johnson, AbbVie shore up Imbruvica's CLL lead with Gazyva combo winAdd another indication for Imbruvica in chronic lymphocytic leukemia to the list. On Monday, partners AbbVie and Johnson & Johnsonsaidthe standout drug had picked up another FDA approval in the d2019/1/24
-
CVS puts Amgen's Aimovig in back seat behind Teva, Lilly migraine drugsAmgen may have the first-mover advantage in the new class of CGRP migraine prevention drugs, but the company didn't get top billing with one major pharmacy benefits manager. CVS gave that to Teva and2019/1/23
-
AstraZeneca's latest value-based pact serves up Brilinta at generic-level copaysAstraZeneca is no stranger to value-based pricing agreements, even for heart drug Brilinta,but its latest is different. The company has struck a deal with UPMC Health Plan that links reimbursement fo2019/1/23
-
FDA panel split on Sanofi's Type 1 diabetes hopeful ZynquistaShould the FDA approve Sanofi’s SGLT1/2 candidate for patients with Type 1 diabetes? Turns out, the experts can’t agree. On Thursday, an advisory panel was split—voting 8-8—on whether the overall ben2019/1/22